Seeking Alpha

Glaxo bribery claims stretch to Syria

  • GlaxoSmithKline (NYSE:GSK) is now facing corruption claims in Syria, where it's has been accused of bribery to secure business.
  • The drugmaker is investigating the claims which date back to 2010 after a whistleblower's email was sent to the company.
  • Syria is now the sixth country to be investigated by Glaxo for smaller-scale bribery claims compared to the $480M Chinese allegations which have plagued the company since last July.
  • GSK -0.2% AH
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector